Ghrelin-receptor / GH secretagogue
GHRP-6
ClinicalThe unnatural peptide that led researchers to ghrelin.
- Cited sources
- 3
- Human-tested claims
- 2 of 3
- Best evidence
- Tier 2 · Clinical
- Status
- Research-only
The original growth-hormone-releasing peptide, a synthetic hexapeptide designed in the 1980s before anyone knew what receptor it hit. The hunt for that receptor produced ghrelin. It releases GH in people by every route tested, raises cortisol as well, and was never developed as a drug.
How it works
GHRP-6 is a ghrelin-receptor (GHS-R1a) agonist. It was built by trial and error from enkephalin fragments; its receptor was cloned in 1996 and the natural ligand, ghrelin, was found in 1999. It stimulates GH directly at the pituitary and through the hypothalamus, and in people it also stimulates ACTH and cortisol and provokes hunger.
Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂A hexapeptide with two D-amino acids, so no one-letter form applies.
What it's studied for
One claim per card, each with its own tier and source. Tiers 1 and 2 are human data. Tiers 3 and 4 are not yet.
- [1]Frieboes et al., 1995 (Neuroendocrinology)(opens in a new tab)
Raised overnight GH, ACTH and cortisol and increased stage 2 sleep in healthy men (placebo-controlled).
Clinical - [2]Bellone et al., 1995 (Eur J Endocrinol)(opens in a new tab)
Given orally to short-statured children, produced a GH response comparable to intravenous GHRH.
Clinical - [3]Bowers, 2001 (J Clin Endocrinol Metab review)(opens in a new tab)
Acts at the ghrelin receptor; its discovery led to the identification of GHS-R and of ghrelin itself.
Preclinical
Safety & limitations
In healthy men it raised ACTH and cortisol overnight alongside GH, the opposite of GHRH, which blunts cortisol. That is the clearest difference from ipamorelin, and the reason 'selective' secretagogues were developed.
[1]Frieboes et al., 1995 (Neuroendocrinology)(opens in a new tab)No long-term human safety data exist. The hunger-promoting effect of ghrelin-receptor agonists is well documented and is a feature, not a side effect, of the mechanism.
[3]Bowers, 2001 (J Clin Endocrinol Metab review)(opens in a new tab)Regulatory & legal status
Never approved in any jurisdiction. A research tool with a short human-study record in the 1990s, now sold in grey markets.
[3]Bowers, 2001 (J Clin Endocrinol Metab review)(opens in a new tab)Frequently asked
How does GHRP-6 differ from ipamorelin?
Same receptor, different selectivity. GHRP-6 raises cortisol and prolactin along with GH in human studies; ipamorelin was engineered to avoid that, at least in preclinical work. GHRP-6 is also the stronger appetite stimulant.
References
Written by Twenty Residues editorial. Medical review: pending; a named reviewer is being assigned.
Last updated October 1, 2026.
Spot an error or a better source? Report a correction. Every change is logged below.
Update history
- 2026-10-01 — Entry added.